ARTL
Artelo Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.91
−4.98%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -15.8%
- EBIT
- -5.1%
- EPS
- —
- Free cash flow
- -89.9%
- Operating cash flow
- -89.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +70.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -27.6%
- EBIT
- -12.8%
- Net income
- -31.1%
- EPS
- —
- Free cash flow
- -2.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026